LYNPARZA is a type of targeted therapy called a PARP inhibitor. It’s used to treat adults who have an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer that has been treated with chemotherapy, and if HR-positive, treated with hormonal therapy.
Cancer can begin when cells grow out of control. Due to this growth, cancer cells have a higher risk of DNA damage.
To help repair this damage and survive, the cancer cells rely on several different methods, including one that involves the PARP enzyme.
By helping to stop PARP, LYNPARZA can limit a cancer cell’s ability to repair DNA damage. And that can lead to cancer cell death. LYNPARZA may also impact other cells and tissues in the body.
Learn more about how PARP inhibitors work in breast cancer.
The purpose of this study was to see how safe and effective LYNPARZA is as a treatment for patients with an inherited BRCA mutation and HER2-negative metastatic breast cancer who were treated with chemotherapy, and if HR-positive, treated with hormonal therapy.
There are a few ways for researchers to see if LYNPARZA is working. In this study, health care providers measured how long LYNPARZA delayed disease progression, which means they measured how long women lived without their cancer getting worse.
LYNPARZA was studied in 302 patients with an inherited BRCA mutation and HER2-negative metastatic breast cancer who were treated with chemotherapy. Patients were either HR-positive (50%) or triple negative (50%). 205 patients were given 2 LYNPARZA tablets (150 mg each) 2 times a day, and 97 patients were given certain chemotherapies chosen by their health care provider.
Delayed progression by 7 months
The primary results of the study showed that LYNPARZA delayed disease progression by a median of 7 months compared with 4.2 months for patients who were given certain chemotherapies. This means that LYNPARZA slowed the progression of cancer 60% longer than certain chemotherapies.
LYNPARZA reduced the risk of cancer growing, spreading, or getting worse by 42% compared with certain chemotherapies.
The most common adverse reactions included anemia, a low count of white blood cells, nausea, vomiting, diarrhea, respiratory tract infection, tiredness or weakness, and headache. Other adverse reactions included cough, loss of appetite, low number of blood platelets, changes in how food tastes, a low count of white blood cells, dizziness, indigestion, mouth sores, pain or discomfort in the stomach area, rash, increase in creatinine, and eczema. Because of an adverse reaction, 35% of patients interrupted treatment with LYNPARZA, and 28% interrupted treatment with chemotherapy; 25% of patients had their LYNPARZA doses reduced, and 31% had their chemotherapy doses reduced; and 5% of patients stopped treatment with LYNPARZA, and 8% stopped treatment with chemotherapy. These are not the only side effects associated with LYNPARZA.
Ask your health care provider what LYNPARZA may do for you.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects. The most common side effects of LYNPARZA are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here.